Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease

Eur J Pharm Sci. 2020 May 30:148:105314. doi: 10.1016/j.ejps.2020.105314. Epub 2020 Mar 19.

Abstract

Quercetin was encapsulated in lipid nanoparticles (SLN and NLC) to take advantage of its neuroprotective properties in Alzheimer's disease. The nanoparticles were functionalized with transferrin to facilitate the passage across the blood-brain barrier through the transferrin receptors overexpressed in brain endothelial cells. NMR and FTIR confirmed the functionalization of the nanoparticles with transferrin. TEM results showed all nanoparticles presented spherical morphology. Nanoparticles exhibited size around 200 nm and zeta potential values higher than -30 mV. Quercetin entrapment efficiency was around 80-90%. LDH cytotoxicity assays in hCMEC/D3 cell line demonstrated that even for the highest concentration (30 μM) nanoparticles did not reveal cytotoxicity after 4 h of incubation. Permeability studies across hCMEC/D3 cell monolayers showed NLC permeate more the blood-brain barrier, while amyloid-beta studies demonstrated NLC-transferrin have the capacity to inhibit fibril formation. Nanoparticles seem to be suitable for brain applications, mainly for Alzheimer's disease due to inhibition of amyloid-beta aggregation.

Keywords: Amyloid-beta peptide; Blood-brain barrier; Nanostructured lipid carriers (NLC); Solid lipid nanoparticles (SLN); Transferrin receptors.

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Amyloid beta-Peptides
  • Blood-Brain Barrier / metabolism
  • Brain / metabolism
  • Cell Line
  • Cell Survival
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods*
  • Endothelial Cells / metabolism
  • Humans
  • Lipids / chemistry
  • Nanoparticles / chemistry*
  • Particle Size
  • Quercetin / administration & dosage*
  • Quercetin / metabolism
  • Transferrin / chemistry

Substances

  • Amyloid beta-Peptides
  • Drug Carriers
  • Lipids
  • Transferrin
  • Quercetin